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INTRODUCTION
Facioscapulohumeral muscular dystrophy (FSHD, MIM 
#158900) is the most common myopathy in adults, with an 
overall incidence greater than 1:10000. FSHD is transmitted as 
an autosomal dominant inherited muscle disorder and is 
clinically characterized by asymmetric weakness of facial, 
shoulder girdle, trunk, and upper arm muscles that progresses 
to involve humeral, anterior lower leg, and pelvic girdle mus-
cles, with prominent abdominal muscle weakness. It can also 
be accompanied by retinal telangiectasia or central nervous 
system involvement (mental retardation and epilepsy).1
FSHD1, the major subtype of FSHD, is the result of chroma-
tin relaxation by pathogenic contraction of a macrosatellite 
repeat, called D4Z4, on the 4q subtelomere of a 4qA allele and 
a functional polyadenylation signal. However, not all patients 
with the FSHD clinical phenotype manifest D4Z4 pathogenic 
contraction.2 Five percent of FSHD patients have a low to nor-
mal number of repeats on chromosome 4q35. Instead, they 
show profound DNA hypomethylation with pathogenic vari-
ants of the SMCHD1 or DNMT3B gene and the 4qA variant 
with a polyadenylation signal.3 These patients are diagnosed 
with FSHD2 due to the similar clinical phenotype with FSHD1. 
While FSHD2 patients were first reported in Western countries 
and then in Japan, there have been no reports of FSHD2 in Ko-
rea. We report two Korean patients with FSHD2 due to a novel 
frameshift and a reported point mutation in the SMCHD1 gene. 
CASE REPORT
Case 1
A 40-year-old male visited our clinic for asymmetric upper and 
lower extremity weakness. The patient reported that he had 
suffered bilateral shoulder weakness since the age of 10 years. 
When he was 13-years-old, he presented with a right winged 
scapula. In addition, he reported bilateral leg weakness since 
he was 24 years old. Physical examination revealed a trans-
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verse smile; winged scapula; “Popeye” arm appearance; facial 
weakness; and asymmetric, proximal dominant arm and leg 
weakness (right side more severe than the left). Serum creati-
nine kinase levels were mildly elevated at 319 unit/L. His fa-
ther and elder brother had similar symptoms (Fig. 1A). His el-
der brother had been visiting another hospital for similar 
symptoms since he was 10 years old, and his muscle pathology 
showed severe chronic myopathic changes (marked increased 
size variability, hypertrophic fibers, degenerating and atro-
phic fibers, endomysial fibrosis and mild fatty infiltration, dis-
ruption of intermyofibrillar network, and lobulated fibers) 
with normal dystrophin immunoreactivity. The elder brother 
was diagnosed with FSHD based on clinical phenotype, but 
refused a genetic study. However, our patient agreed to un-
dergo genetic analysis for diagnosis. Therefore, we performed 
conventional Southern blot analysis with EcoRI and BlnI en-
zymes, but the D4Z4 repeat size was 12, which is normal. Next, 
whole exome sequencing revealed a novel frameshift mutation 
(c.3801delG, p.Glu1267Aspfs*5) in SMCHD1 [Fig. 1B, upper (pa-
tient) and lower (mother) panels], a mutation that has not been 
described in previous reports or public databases (ExAC, 
ESP6500, 1000 genome). Finally, methylation-sensitive South-
ern blot analysis with FseI showed mildly reduced D4Z4 re-
peat size on 4q (41kb/39kb) and reduced D4Z4 methylation 
ratio (14.6%). Accordingly, we could report our case 1 as “patho-
genic” and carrying a novel variant, as indicated in ACMG-
AMP guidelines.4 
Case 2
A 38-year-old male visited our clinic for asymmetric upper ex-
tremity weakness. The patient reported that, at the age of nine, 
he had difficulty performing iron bar gymnastics. Since his 
third decade, he experienced prominent right shoulder and 
arm weakness, and he presented with facial asymmetry and 
weakness. Physical examination showed a transverse smile, 
positive Beevor’s sign, and winged scapula (Fig. 2B). In addi-
tion, he showed facial and bilateral arm and leg weakness 
with proximal dominance and asymmetricity (right side more 
severe than the left) on neurological examination. Serum cre-
atinine kinase levels were mildly elevated at 224 unit/L. His 
mother and elder sister had similar symptoms (Fig. 2A). We 
performed genetic analysis for FSHD. Southern blotting anal-
ysis by the EcoRI/BlnI digestion method using genomic DNA 
revealed that a fragment size of 37 kb, and the number of D4Z4 
repeats was nine. Bisulfite sequencing to determine the haplo-
type of D4Z4 using digestion with HindIII and hybridized with 
4qA probe and target sequencing analysis to screen for muta-
tions in the SMCHD1 gene by a next-generation sequencer (Ion 
PGMTM) were performed for FSHD2 diagnosis. We found re-
duced DNA methylation ratio (16.8%), D4Z4 haplotype 4qA 
(homozygous), and c.1580C>T (p.T527M) SMCHD1 mutation, 
which was previously reported to be a pathogenic allele.5
Informed consent was obtained from the two patients re-
garding the reporting and publication of this case report. 
DISCUSSION
We report the first two cases of FSHD2 in Korea. Since 2008, 
there have been some reports in patients with FSHD1. In Ko-
rea, all studies of FSHD have been performed in patients with 
confirmation of D4Z4 contraction.6-8 Those studies reported 
the following; 1) facial muscles are initially affected, and an 
asymmetric face and shoulder girdle weakness, winging scap-
ular, transverse smile, and Beevor’s sign are important find-
ings;7 2) most Korean FSHD1 patients (102/108 patients, 94.4%) 
carry one to six units of D4Z4 repeat;6,8 3) female are more se-
verely affected than male, even though there are no differences 
Fig. 1. Family pedigree and validation data of case 1. (A) Pedigree. The patient’s father and elder brother showed similar symptoms. Arrow: patient. (B) Vali-
dation. Upper, patient; Lower, patient’s mother. 
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in age at examination or in D4Z4 copy number between the 
two sexes.8 
In case 1, the patient and his brother showed the typical 
FSHD phenotype; however, a conventional Southern blot study 
showed low to normal D4Z4 repeat size. Re-analysis of the 
D4Z4 repeat size showed mild contraction (nine repeats). In 
case 2, Southern blot analysis showed nine D4Z4 repeats. Pre-
vious Korean and Japanese reports of patients with FSHD,8,9 
revealed that most East Asian FSHD1 patients have one to six 
D4Z4 repeats, although four of 13 FSHD2 patients in Japan had 
nine to 10 D4Z4 repeats.9 The two present cases had nine ho-
mozygous repeats or 9/10 repeats of D4Z4. Considering previ-
ously reported genetic profiles of East Asian FSHD1 and FSHD2 
cases, FSHD2 is a more likely diagnosis than FSHD1+2 or FSHD1 
for diagnosis in our cases. SMCHD1 mutation has been report-
ed as modifier of disease severity in FSHD families,5 although 
through some case series and studies, researchers have sug-
gested that mildly contracted D4Z4 repeats with SMCHD1 mu-
tation may be important for the development.9 
The mutation in case 1 was a frameshift mutation causing a 
truncated protein, and we confirmed that DNA methylation 
was decreased. Lemmers, et al.2 previously reported 45 muta-
tions in 51 of 60 families with FSHD2. Two families from the 
USA and South Korea showed a splicing site mutation (c.3801+ 
1G>A, exon 29 skipping) near the site of the mutations, similar 
to the present cases, but a different type of mutation. 
Mild dysphagia in early stages was observed in some pa-
tients (3 of the 13 patients) with SMCHD1 mutations in a Japa-
nese study,9 and they did not find any other clinical findings 
of FSHD2. Dysphagia is commonly presented in FSHD at late 
advanced stages.1 Our patients did not have any subjective 
swallowing difficulty. Unfortunately, we did not perform objec-
tive evaluation for dysphagia, and thus we do not know wheth-
er they had “silent aspiration” without any cough or outward 
signs of aspiration. Dysphagia could be a distinctive feature of 
FSHD2, but needs additional study. 
We report the first confirmed cases of FSHD2 due to novel 
frameshift mutation and reported point mutation in Korea 
with detailed clinical manifestation. We suggest genetic analy-
sis of the D4Z4 haplotype and methylation as important diag-
nostic steps for accurate diagnosis of FSHD, and whole exome 
sequencing is another option in Korea.
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